Skip the primary navigation if you do not want to read it as the next section.
Skip the main content if you do not want to read it as the next section.
Europe is first to gain access to a new therapy for partial seizures
Today (13 September) saw the launch of a new type of epilepsy drug called perampanel.
Perampanel, also known by its brand name Fycompa, has shown in clinical trials to be effective in the treatment of partial onset seizures, in particular with secondary generalisations.
Perampanel is the first and only licensed anti-epileptic drug (AED) to selectively target AMPA receptors, a receptor in the brain which plays a critical role in the initiation and spread of seizures. This mechanism of action is different to any other licensed AEDs. In addition, perampanel only needs to be taken once a day at bedtime.
Epilepsy Society’s Dr Fergus Rugg-Gunn said: “The successful management of partial onset seizures remains a significant challenge in many epilepsy patients, and the incidence of uncontrolled seizures remains too high, despite existing treatments. Perampanel provides doctors and patients with an important new option for the treatment of partial onset epilepsy and may play a key role in improving seizure management in poorly controlled adults and adolescents.”
In the UK and Europe, perampanel is indicated for use as an adjunctive treatment for partial onset seizures, the most common type of epilepsy, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.
More information from http://www.eisai.com/news/news201266.html
Author: Angie King